Killing two birds with a stone: how to maximise benefit from metastasis-directed therapy and modern systemic treatment in oligometastatic hormone sensitive prostate cancer.
Androgen deprivation therapy
Oligometastatic prostate cancer
PSMA PET/CT
Stereotactic ablative radiotherapy
Journal
Clinical & experimental metastasis
ISSN: 1573-7276
Titre abrégé: Clin Exp Metastasis
Pays: Netherlands
ID NLM: 8409970
Informations de publication
Date de publication:
12 2022
12 2022
Historique:
received:
22
09
2022
accepted:
28
09
2022
pubmed:
16
10
2022
medline:
9
11
2022
entrez:
15
10
2022
Statut:
ppublish
Résumé
Recent findings confirmed benefit from metastasis-directed therapy in oligometastatic hormone sensitive prostate cancer (omHSPC). However, current landscape of systemic treatment suggests that patients could benefit, at the same time, from early initiation of intensified hormonal treatments. In this commentary, we performed an overview about literature evidence aiming to overcome this issue and provide the maximum clinical benefit to the patients, taking advantage of modern imaging (e.g. PSMA PET/CT), ablative local treatment and newest systemic therapies.
Identifiants
pubmed: 36242700
doi: 10.1007/s10585-022-10187-2
pii: 10.1007/s10585-022-10187-2
doi:
Substances chimiques
Hormones
0
Banques de données
ClinicalTrials.gov
['NCT03449719', 'NCT05022914']
Types de publication
Letter
Langues
eng
Sous-ensembles de citation
IM
Pagination
841-843Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Nature B.V.
Références
Deek MP, Van der Eecken K, Sutera P et al (2022) Long-term outcomes and genetic predictors of response to metastasis-directed therapy versus observation in oligometastatic prostate cancer: analysis of STOMP and ORIOLE trials. J Clin Oncol. https://doi.org/10.1200/JCO.22.00644
doi: 10.1200/JCO.22.00644
pubmed: 36001857
Ost P, Reynders D, Decaestecker K et al (2018) Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter Phase II trial. J Clin Oncol 36:446–453. https://doi.org/10.1200/JCO.2017.75.4853
doi: 10.1200/JCO.2017.75.4853
pubmed: 29240541
Phillips R, Shi WY, Deek M et al (2020) Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE Phase 2 randomized clinical trial. JAMA Oncol 6:650–659. https://doi.org/10.1001/jamaoncol.2020.0147
doi: 10.1001/jamaoncol.2020.0147
pubmed: 32215577
pmcid: 7225913
Chi KN, Chowdhury S, Bjartell A et al (2021) Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, Phase III TITAN study. J Clin Oncol 39:2294–2303. https://doi.org/10.1200/JCO.20.03488
doi: 10.1200/JCO.20.03488
pubmed: 33914595
Armstrong AJ, Azad AA, Iguchi T et al (2022) Improved survival with enzalutamide in patients with metastatic hormone-sensitive prostate cancer. J Clin Oncol 40:1616–1622. https://doi.org/10.1200/JCO.22.00193
doi: 10.1200/JCO.22.00193
pubmed: 35420921
pmcid: 9113211
Glicksman RM, Ramotar M, Metser U et al (2022) Extended results and independent validation of a phase 2 trial of metastasis directed therapy for molecularly defined oligometastatic prostate cancer. Int J Radiat Oncol Biol Phys 25:S0360-3016(22)00644-7. https://doi.org/10.1016/j.ijrobp.2022.06.080 .